KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.

Rebecca McKetin, Steven Shoptaw, Lucy Saunders, Long Nguyen, Philip J Clare, Gregory J Dore, Alyna Turner, Olivia M Dean, Peter J Kelly, Shalini Arunogiri, Juanita Koeijers, Tayla J Degan, Louisa Degenhardt, Michael Farrell, David Goodman-Meza, Barbara Sinclair, David Reid, Frank Cordaro, Harry Hill, Robert Lundin, Jeremy Hayllar, Michael Christmass, Willy Liaw, Danica Liu, Amelia Woods, Blaire Brewerton, Ellie Holyoak, Brian Tid-Fung Wu, Hayley Maher, Noni O'Dea, Joel Keygan, Ava Kontogiannis, Lily Palmer, Caity Morrison, Anna Wrobel, Bec Hyland, Gift Kiden, Vanessa Romeo, Khine Wut Yee Kyaw, Marianne Byrne, Samantha Colledge-Frisby, Emma Zahra, Michael Berk

JAMA Psychiatry 83(6) 581-589

PMID41920558
PMCIDPMC13044789
DOI10.1001/jamapsychiatry.2026.0159
发表日期2026-04-01
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图。
摘要

摘要

IMPORTANCE: Methamphetamine use disorder is a global health challenge for which there are no approved pharmacotherapies. The safety and effectiveness of mirtazapine, a promising candidate for methamphetamine use disorder, has not been established in routine clinical practice. OBJECTIVE: To determine the safety and effectiveness of mirtazapine as a pharmacotherapy for methamphetamine use disorder in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, parallel-group, double-blind, placebo-controlled randomized clinical trial was conducted between November 16, 2022, and May 1, 2025, at 6 outpatient alcohol and other drug clinics in Australia among adults with moderate to severe methamphetamine use disorder. Data analysis was conducted from May to September 2025. INTERVENTION: Mirtazapine (30 mg daily for 12 weeks) or equivalent placebo. MAIN OUTCOMES AND MEASURES: The primary end point was the change in days of methamphetamine use in the past 28 days from baseline to week 12. Secondary end points were depression, insomnia, HIV risk behavior, quality of life, and methamphetamine-negative oral fluid samples. RESULTS: Of 344 participants randomized, 339 participants received the intervention (167 in the placebo group and 172 in the mirtazapine group). Mean (SD) age was 42.0 (8.6) years, 126 participants (37.2%) were female, and participants had used methamphetamine for a median (IQR) of 24 days (17-28) of the past 28 days at baseline. The mean reduction in days of methamphetamine use from baseline to week 12 was greater in the mirtazapine group (7.0 days of 28 days) than in the placebo group (4.8 days of 28 days; mean difference, 2.2 days; 95% CI, -4.2 to -0.2 days; P = .02). More participants in the mirtazapine group reported drowsiness (47% vs 33%) and weight gain (10% vs 3%). Forty participants (23%) discontinued mirtazapine due to adverse events compared to 25 participants (15%) in the placebo group. No significant effects of mirtazapine on secondary end points were found. CONCLUSIONS AND RELEVANCE: In this parallel-group randomized clinical trial, mirtazapine delivered in routine clinical practice reduced methamphetamine use in adults with methamphetamine use disorder. No unexpected safety concerns delivering mirtazapine in this setting were found; this finding has important clinical implications in the absence of any approved pharmacotherapies for methamphetamine use disorder. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12622000235707.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. CONSORT Flow Diagram
非 KM Figure
Figure 2Figure 2.. Forest Plot Showing Treatment Estimands by Whether Participants Were Depressed at Eligibility Bars represent the mean (95% CI) treatment estimand at week 12 for mirtazapine vs placebo by whether participants were not depressed (Patient Health Questionnaire–9 [PHQ-9] score < 10) or depressed (PHQ-9 score ≥10) on entry to the trial. End points on the y-axis (from top to bottom): the number of days of methamphetamine use in the past 28 days assessed using the timeline follow-back method; the percentage of methamphetamine-negative oral fluid tests taken at weeks 4, 8, and 12; depression score on the PHQ-9; insomnia score on the Athens Insomnia Scale, 5-item version; HIV risk behavior score on the HIV Risk-Taking Behavior Scale of the Opioid Treatment Index; and quality of life utility score on the EuroQol-5D.
非 KM Figure